Two key factors behind NYC's record-setting rise in healthcare funding

According to a new report, women’s and digital health led to an explosion in funding last year in NYC.

By Robin Robinson • March 7, 2022

Succeed when others fail: Avoiding 20% in investment waste during launch

Approximately 20% of pharma spend during launch is wasted. You can right-size spending during launch & across the lifecycle.

March 7, 2022

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Are patients happy? This simple question could shake up clinical trials

The migration to DCTs is helping uncover critical gaps in patient experience.

By Kelly Bilodeau • March 4, 2022

Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started

The company’s CEO on the road ahead for AI capabilities in pharma.

By Meagan Parrish • March 4, 2022

Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter

With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.

By Taren Grom • March 2, 2022

The 2022 PharmaVoice 100 — new look, same drive for excellence

Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.  

By Taren Grom • Feb. 28, 2022

Reaching the rare: How can we best support and engage with the rare disease community during the pandemic?

How can we better understand the challenges defining the pandemic journey of a rare disease patient?

Feb. 28, 2022

Guadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues

A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company. 

By Robin Robinson • Feb. 25, 2022

Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo

Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.

By Taren Grom • Feb. 23, 2022

Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market

The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.

By Kelly Bilodeau • Feb. 23, 2022

Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler

Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.

By Taren Grom • Feb. 16, 2022

Winning buy-in from early stage biotech investors

The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.

By Taren Grom • Feb. 11, 2022

Industry executives on the milestone moments shaping pharma's future

Scientific, technological, and communication changes that are making a permanent impact on the industry.

By Taren Grom • Feb. 9, 2022

Innovation vs. invention

IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.

By Taren Grom • Feb. 9, 2022

Saniona's CEO on why it takes a village to develop treatments for a rare disease

Saniona built its village by first hiring a head of patient advocacy.

By Kim Ribbink • Feb. 8, 2022

Why 23andMe's first solo clinical trial is a big deal

It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come. 

By Taren Grom • Feb. 7, 2022

Home is where the trial is

Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials. 

By Kelly Bilodeau • Feb. 7, 2022

Pharma's pain points with AI

Looking beyond the buzz and at the challenges associated with AI.

By Meagan Parrish • Feb. 7, 2022

Ferring Pharmaceuticals president discusses the need for more funding in women's health research

Read why women's healthcare funding is such a challenge.

By Robin Robinson • Feb. 4, 2022

Industry executives predict the next 'blue oceans' in pharma

Where life science leaders see breakthroughs happening in the industry.

By Taren Grom • Feb. 4, 2022

Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics

With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.

By Robin Robinson • Feb. 3, 2022

Woman of the Week: Syneos Health's president of commercial solutions, Michelle Keefe

How Michelle Keefe, president, commercial solutions at Syneos Health, steered her team into a rapid pivot during the pandemic.

By Taren Grom • Feb. 2, 2022

Talent acquisition stays top of mind for pharma execs

From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.

By Taren Grom • Feb. 1, 2022

For the CEO of Travere, running a rare disease company is personal

To kick off Rare Disease month, we interview the CEO of Travere Therapeutics

By Kim Ribbink • Feb. 1, 2022

Biopharma's R&D leaders on how technology can accelerate drug development

How emerging digital tools are providing enhanced clinical insights and improved trial results.

By Taren Grom • Jan. 27, 2022